Reversibility of trastuzumab cardiotoxicity: Is the concept alive and well?

被引：18

作者：

Ewer, Michael S. ^{[1
]}

Tan-Chiu, Elizabeth ^{[2
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Cardiol, Houston, TX 77030 USA

[2] Florida Canc Res Inst, Davie, FL USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 34期

关键词：

D O I：

10.1200/JCO.2007.14.0657

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：5532 / 5533

页数：2

共 8 条

[1]

DEKORTE M, EUR J CANC, V43, P2046

[2] The anthracycline-trastuzumab interaction: Up-regulated binding may provide vital mechanistic insight [J].

Ewer, Michael S. .

EUROPEAN JOURNAL OF CANCER, 2007, 43 (14) :2024-2025

[3] Type II chemotherapy-related cardiac dysfunction: Time to recognize a new entity [J].

Ewer, MS ;

Lippman, SM .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (13) :2900-2902

[4] Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment [J].

Ewer, MS ;

Vooletich, MT ;

Durand, JB ;

Woods, ML ;

Davis, JR ;

Valero, V ;

Lenihan, DJ .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) :7820-7826

[5] Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: The M.D. Anderson Cancer Center experience [J].

Guarneri, Valentina ;

Lenihan, Daniel J. ;

Valero, Vicente ;

Durand, Jean-Bernard ;

Broglio, Kristine ;

Hess, Kenneth R. ;

Michaud, Laura Boehnke ;

Gonzalez-Angulo, Ana M. ;

Hortobagyi, Gabriel N. ;

Esteva, Francisco J. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (25) :4107-4115

[6] Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial [J].

Suter, Thomas M. ;

Procter, Marion ;

van Veldhuisen, Dirk J. ;

Muscholl, Michael ;

Bergh, Jonas ;

Carlomagno, Chiara ;

Perren, Timothy ;

Passalacqua, Rodolfo ;

Bighin, Claudia ;

Klijn, Jan G. M. ;

Ageev, Fail T. ;

Hitre, Erika ;

Groetz, Juergen ;

Iwata, Hiroji ;

Knap, Malgorzata ;

Gnant, Michael ;

Muehlbauer, Susanne ;

Spence, Alison ;

Gelber, Richard D. ;

Piccart-Gebhart, Martine J. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (25) :3859-3865

[7] Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31 [J].

Tan-Chiu, E ;

Yothers, G ;

Romond, E ;

Geyer, CE ;

Ewer, M ;

Keefe, D ;

Shannon, RP ;

Swain, SM ;

Brown, A ;

Fehrenbacher, L ;

Vogel, VG ;

Seay, TE ;

Rastogi, P ;

Mamounas, EP ;

Wolmark, N ;

Bryant, J .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) :7811-7819

[8] Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility [J].

Telli, Melinda L. ;

Hunt, Sharon A. ;

Carlson, Robert W. ;

Guardino, Alice E. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (23) :3525-3533

← 1 →